Printer Friendly

Articles from M2 Pharma (June 5, 2019)

1-15 out of 15 article(s)
Title Author Type Words
AGC Biologics names Kasper Moller new chief technical officer. 174
Apollo Medical Holdings acquires USD45m Alpha Care Medical Group. 195
AstraZeneca and Merck reveal complete results from phase three SOLO3 LYNPARZA trial. 180
Bio-Techne closes acquisition of B-MoGen Biotechnologies Inc. 182
Biosight awarded US FDA orphan drug designation for BST-236 to treat AML. 202
Eisai names new vice president and chief financial officer. 153
Eli Lilly and Company wins US FDA approval for Emgality (galcanezumab-gnlm) injection (300 mg) for episodic cluster headache. 310
Gore announces US FDA PMA for the GORE CARDIOFORM ASD Occluder to treat atrial septal defects. 279
Intensity Therapeutics Presents Positive Preliminary Phase 1/2 Results for Intratumoral Injection of INT230-6 at ASCO 2019. 516
Moderna Presents Interim Data from Phase 1 Study of mRNA Personalised Cancer Vaccine at 2019 ASCO Annual Meeting. 647
ReWalk Robotics Ltd wins US FDA clearance for ReStore soft exo-suit system for stroke survivors with mobility challenges across the US. 299
The European Commission grants conditional marketing authorisation to bluebird bio's ZYNTEGLO. 208
The US FDA approves new indication for Merck's Zerbaxa. 147
Vaccitech begins Phase 2b clinical study of MVA-NP+M1 universal flu vaccine (VTP-100) in Belgium and concludes recruitment in Australia. 290
Zavation awarded US FDA clearance for the Ti3Z Interbody System (TLIF, T-PLIF, and PLIF) body fusion implant device. 283

Terms of use | Privacy policy | Copyright © 2026 Farlex, Inc. | Feedback | For webmasters |